Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 32

1.

Long-Term Survival and Complete Response to Anastrozole in Breast Cancer Patient With Cutaneous Metastases Only.

Sedloev T, Vlahova A, Usheva S, Vasileva-Slaveva M, Spiridonova T, Spirdonov J.

Anticancer Res. 2019 Aug;39(8):4393-4398. doi: 10.21873/anticanres.13609.

PMID:
31366535
2.

Subcutaneous Testosterone Anastrozole Therapy in Men: Rationale, Dosing, and Levels on Therapy.

Glaser RL, York AE.

Int J Pharm Compd. 2019 Jul-Aug;23(4):325-339.

PMID:
31315085
3.

Temperature/pH-Triggered PNIPAM-Based Smart Nanogel System Loaded With Anastrozole Delivery for Application in Cancer Chemotherapy.

Singh A, Vaishagya K, K Verma R, Shukla R.

AAPS PharmSciTech. 2019 Jun 4;20(5):213. doi: 10.1208/s12249-019-1410-3.

PMID:
31165298
4.

Primary antiphospholipid syndrome during aromatase inhibitors therapy: A case report and review of the literature.

Tenti S, Giordano N, Cutolo M, Giannini F, Fioravanti A.

Medicine (Baltimore). 2019 Mar;98(13):e15052. doi: 10.1097/MD.0000000000015052. Review.

5.

Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer.

Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Linden HH, Livingston RB, Hortobagyi GN.

N Engl J Med. 2019 Mar 28;380(13):1226-1234. doi: 10.1056/NEJMoa1811714. Erratum in: N Engl J Med. 2019 Jun 6;380(23):2282.

PMID:
30917258
6.

Idiopathic gonadotropin-independent precocious puberty - is regular surveillance required?

Arya VB, Davies JH.

J Pediatr Endocrinol Metab. 2019 Apr 24;32(4):403-407. doi: 10.1515/jpem-2018-0419.

PMID:
30849047
7.

[Follicle-Stimulating Hormone and Estradiol Levels in Japanese Women Treated with Toremifene and Anastrozole for Two Years - A Retrospective Analysis of Data from a Prospective Randomized Trial].

Anan K, Mitsuyama S, Yanagita Y, Kimura M, Doihara H, Komaki K, Kusama M, Ikeda T.

Gan To Kagaku Ryoho. 2018 Dec;45(12):1725-1728. Japanese.

PMID:
30587728
8.

Aromatase inhibitor therapy for endometrial stromal sarcoma - two-centre experience.

Serkies K, Abacjew-Chmyłko A, Wieczorek-Rutkowska M, Pęksa R.

Ginekol Pol. 2018;89(11):607-610. doi: 10.5603/GP.a2018.0104.

9.

Pharmacokinetic evaluation of a transdermal anastrozole-in-adhesive formulation.

Regenthal R, Voskanian M, Baumann F, Teichert J, Brätter C, Aigner A, Abraham G.

Drug Des Devel Ther. 2018 Nov 1;12:3653-3664. doi: 10.2147/DDDT.S170764. eCollection 2018.

10.

Are aromatase inhibitors associated with higher myocardial infarction risk in breast cancer patients? A Medicare population-based study.

Kamaraju S, Shi Y, Smith E, Nattinger AB, Laud P, Neuner J.

Clin Cardiol. 2019 Jan;42(1):93-100. doi: 10.1002/clc.23114. Epub 2018 Dec 7.

11.

Clinical outcomes comparison of 10 years versus 5 years of adjuvant endocrine therapy in patients with early breast cancer.

Li L, Chang B, Jiang X, Fan X, Li Y, Li T, Wu S, Zhang J, Kariminia S, Li Q.

BMC Cancer. 2018 Oct 12;18(1):977. doi: 10.1186/s12885-018-4878-4.

12.

Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study).

Kim JY, Im SA, Jung KH, Ro J, Sohn J, Kim JH, Park YH, Kim TY, Kim SB, Lee KS, Kim GM, Kim SH, Kim S, Ahn JS, Lee KH, Ahn JH, Park IH, Im YH; breast cancer committee of Korean Cancer Study Group (KCSG).

Eur J Cancer. 2018 Nov;103:127-136. doi: 10.1016/j.ejca.2018.08.004. Epub 2018 Sep 14.

PMID:
30223226
13.

Novel 18-gene signature for predicting relapse in ER-positive, HER2-negative breast cancer.

Buus R, Yeo B, Brentnall AR, Klintman M, Cheang MCU, Khabra K, Sestak I, Gao Q, Cuzick J, Dowsett M.

Breast Cancer Res. 2018 Sep 4;20(1):103. doi: 10.1186/s13058-018-1040-9.

14.

Prepubertal gynaecomastia in a boy with Peutz-Jeghers syndrome: managing the aromatase overexpression.

Simões-Pereira J, Santos F, Lopes L, Limbert C.

J Pediatr Endocrinol Metab. 2018 Oct 25;31(10):1149-1154. doi: 10.1515/jpem-2017-0455.

PMID:
30052520
15.

Radiation-induced morphea-a rare but severe late effect of adjuvant breast irradiation : Case report and review of the literature.

Partl R, Regitnig P, Tauber G, Pötscher M, Bjelic-Radisic V, Kapp KS.

Strahlenther Onkol. 2018 Nov;194(11):1060-1065. doi: 10.1007/s00066-018-1336-9. Epub 2018 Jul 16.

16.

Combination therapy with clomiphene citrate and anastrozole is a safe and effective alternative for hypoandrogenic subfertile men.

Alder NJ, Keihani S, Stoddard GJ, Myers JB, Hotaling JM.

BJU Int. 2018 Oct;122(4):688-694. doi: 10.1111/bju.14390. Epub 2018 Jun 6.

PMID:
29873446
17.

Fulvestrant in management of hormone receptor-positive metastatic breast cancer.

Shafaee MN, Ellis MJ.

Future Oncol. 2018 Aug;14(18):1789-1800. doi: 10.2217/fon-2017-0489. Epub 2018 May 22.

PMID:
29783894
18.

Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer.

Bender CM, Merriman JD, Sereika SM, Gentry AL, Casillo FE, Koleck TA, Rosenzweig MQ, Brufsky AM, McAuliffe P, Zhu Y, Conley YP.

Oncol Nurs Forum. 2018 May 1;45(3):308-326. doi: 10.1188/18.ONF.308-326.

19.

Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5.

Dowsett M, Sestak I, Regan MM, Dodson A, Viale G, Thürlimann B, Colleoni M, Cuzick J.

J Clin Oncol. 2018 Jul 1;36(19):1941-1948. doi: 10.1200/JCO.2017.76.4258. Epub 2018 Apr 20.

20.

Erythematous Maculopapular Eruption Induced by Anastrozole: The First Case.

Cozzani E, Trave I, Burlando M, Parodi A.

Am J Ther. 2018 Nov/Dec;25(6):e743-e744. doi: 10.1097/MJT.0000000000000755. No abstract available.

PMID:
29668491

Supplemental Content

Loading ...
Support Center